Is Bellus Health Stock Still a Buy After 30% Earnings Jump?

The biotech continues to make progress on obtaining FDA approval for its chronic-cough therapy.

| More on:
Biotech stocks

Image source: Getty Images

Shares of Bellus Health (TSX:BLU) jumped an astounding 30% last week after the chronic-cough therapy company reported strong earnings. Once a steal, Bellus stock is now back to near 52-week highs. So is this biotech stock still a buy?

What happened with Bellus Health

During the first quarter, management reported they would have an end-of-phase 2 meeting with the Federal Drug Administration in June 2022. This could allow Bellus to enter the third phase in the second half of 2022.

The second phase allowed the company to showcase the effectiveness of its SOOTHE trial. Its BLU-5937 remedy improved the severity and quality of life for those with chronic cough.

Bellus remained in a solid cash position with US$234 million on hand. It announced a net loss of US$14.4 million compared with a loss of US$15.8 million the year before — the improvement was thanks to lower costs surrounding research and development for BLU-5937.

So what?

It’s not just that Bellus is improving its financial position; it’s also getting closer to getting BLU-5937 to market. Chronic cough affects millions of Americans, and the company is also meeting with European agencies to get them on board as well.

Obtaining FDA approval is an enormous milestone for any biotech company. Once a product is approved in the U.S., it allows other countries to fast-track their approvals, which would lead to an enormous increase in revenue for the company.

Now what

A few things. First, management is set to discuss the results of its trials during a thoratic conference in late May. Then of course there is the meeting with the FDA to look forward to in June. Both will allow investors some insight into when we can expect BLU-5937 to come to market.

Meanwhile, analysts remain solidly behind Bellus stock. In particular, they see a high likelihood of the company being able to expand the product on a global scale. Some analysts noted the company will be able to take on an increased market share of up to 32%. Therefore, the company continues to see an increase in its target price.

Bottom line

Bellus looks to be in a strong financial position, with potentially less than a year before its BLU-5937 is available for purchase. With FDA approval, the company would be able to expand rapidly. So even at around $11 per share, investors should watch for more boosts in the future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

More on Coronavirus

Plane on runway, aircraft
Coronavirus

Can Air Canada Double in 5 Years? Here’s What it Would Take

Air Canada (TSX:AC) stock has gone nowhere since 2020. Can this change?

Read more »

Senior housing
Stocks for Beginners

Home Improvement Stocks Are Set to Fall (When They Do, Buy These Like Crazy!)

Home improvement stocks are due to drop further in the coming months. But with solid underpinnings for the sector, it…

Read more »

An airplane on a runway
Coronavirus

Forget Boeing: Buy This Magnificent Airline Stock Instead

Boeing (NYSE:BA) stock is looking risky right now, but Air Canada (TSX:AC) stock? Much less so.

Read more »

Man considering whether to sell or buy
Stocks for Beginners

Goeasy Stock: Buy, Sell, or Hold?

When it comes to smart buys, goeasy stock (TSX:GSY) is up there as one of the smartest money can buy.…

Read more »

Woman has an idea
Stocks for Beginners

Here’s Why Magna International Is a No-Brainer Value Stock

Magna stock (TSX:MG) has been climbing back once more, but still offers huge value for long-term minded investors.

Read more »

Aircraft wing plane
Coronavirus

1 TSX Stock Down 60% That Could Bounce Back Stronger

Air Canada (TSX:AC) stock got severely beaten down in the March 2020 COVID crash. Here's why it's probably not going…

Read more »

A bull and bear face off.
Stocks for Beginners

Down 30% in 3 Months, Is AC Stock a Buy Today?

Air Canada stock (TSX:AC) climbed this year and is still up 10% in the last year, but down 30% in…

Read more »

Airport and plane
Stocks for Beginners

This Bargain Stock Is the Cheapest It’s Been in Years

This top stock still trades below $25 per share, despite much positive movement. A strong opportunity could be in the…

Read more »